Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2019) 134 (Supplement_1): 5051.

https://doi.org/10.1182/blood-2019-124384

Published: 2019

Journal Articles

Integrative Analysis of AML Cell Response to Cytarabine Reveals Synergistic Opportunities Centered on Cholesterol Metabolism

Fangli Chen, MD PhD, Xue Wu, PhD, Rogozea Adriana, Bin Guo, PhD, H. Scott Boswell, MD, George A. Calin, MD PhD, Mircea Ivan, MD PhD, Heiko Konig, MD PhD

Blood (2018) 132 (Supplement 1): 2631.

https://doi.org/10.1182/blood-2018-99-113634

Published: 2018

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Vaibhav Agrawal, MD MBA, Jordyn Griffin, MD, Andrew O'Brien, MD, Robert P. Nelson, Jr., MD, Jodi L. Skiles, MD, Heiko Konig, MD PhD

Blood (2018) 132 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2018-99-114189

Published: 2018

Journal Articles

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Blood (2018) 132 (Supplement 1): 4040.

https://doi.org/10.1182/blood-2018-99-112974

Published: 2018

Journal Articles

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Blood (2018) 132 (Supplement 1): 3999.

https://doi.org/10.1182/blood-2018-99-119755

Published: 2018

Journal Articles

Reduced Chemosensitivity of FLT3/ITD Mutated Cells to Cytarabine and Quizartinib Under Hypoxic Conditions

Heiko Konig, MD PhD, Adriana L Rogozea, Garrett H Kinnebrew, MD, Mircea Ivan, MD PhD

Blood (2016) 128 (22): 1579.

https://doi.org/10.1182/blood.V128.22.1579.1579

Published: 2016

Journal Articles

The Combination Of FLT3 Inhibition and Hypomethylation Confers Synergistic Anti-Leukemic Effects On FLT3/ITD Positive AML Cell Lines and Primary Cells

Heiko Konig, MD PhD, Mark Levis, MD, PhD

Blood (2013) 122 (21): 3965.

https://doi.org/10.1182/blood.V122.21.3965.3965

Published: 2013

Journal Articles

The Sal-Like 1 (SALL1) Protein is Highly Expressed in Primary Bone Marrow Cells Derived From Patients with Acute Myeloid Leukemia.

Heiko Konig, MD, PhD, Susan Kiefer, PhD, Lynn Robbins, Michael Rauchman, MD, Huda S. Salman, MD

Blood (2009) 114 (22): 1285.

https://doi.org/10.1182/blood.V114.22.1285.1285

Published: 2009

Journal Articles

The Polyamide-Chlorambucil Conjugate 1R-Chl Effectively Inhibits Proliferation and Induces Apoptosis in CML Progenitor Cells

Heiko Konig, MD, PhD, C. James Chou, PhD, Joel M. Gottesfeld, PhD, Ravi Bhatia, MD

Blood (2008) 112 (11): 5031.

https://doi.org/10.1182/blood.V112.11.5031.5031

Published: 2008

Journal Articles

Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.

Heiko Konig, MD, Mhairi Copland, MD, Richard Jove, PhD, Tessa L. Holyoake, MD, PhD, Ravi Bhatia, MD

Blood (2007) 110 (11): 2944.

https://doi.org/10.1182/blood.V110.11.2944.2944

Published: 2007

Journal Articles

Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment.

Bin Zhang, MD, PhD, Heiko Konig, MD, Tinisha Mcdonald, BS, Tessa L. Holyoake, MD, PhD, Dario Campana, PhD, Ravi Bhatia, MD

Blood (2007) 110 (11): 3378.

https://doi.org/10.1182/blood.V110.11.3378.3378

Published: 2007

Journal Articles

MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib.

Paul La Rosee, MD, Nicolai Haertel, MD, Thomas Klag, Heiko Konig, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 652.

https://doi.org/10.1182/blood.V110.11.652.652

Published: 2007

Journal Articles

The Dual Src/Abl Kinase Inhibitor SKI-606 Effectively Inhibits Bcr-Abl Kinase Activity and Reduces Proliferation of CML Primitive Progenitor Cells.

Heiko Konig, MD, Simran K. Sindhu, Frank Boschelli, PhD, Tessa L. Holyoake, MD, Stephen J. Forman, MD, Ravi Bhatia, MD

Blood (2006) 108 (11): 1370.

https://doi.org/10.1182/blood.V108.11.1370.1370

Published: 2006

NARROW

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Integrative Analysis of AML Cell Response to Cytarabine Reveals Synergistic Opportunities Centered on Cholesterol Metabolism

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

A Single Institution Comparison of Treatment Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML) Treated in Pediatric and Adult Settings

Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database

Reduced Chemosensitivity of FLT3/ITD Mutated Cells to Cytarabine and Quizartinib Under Hypoxic Conditions

The Combination Of FLT3 Inhibition and Hypomethylation Confers Synergistic Anti-Leukemic Effects On FLT3/ITD Positive AML Cell Lines and Primary Cells

The Sal-Like 1 (SALL1) Protein is Highly Expressed in Primary Bone Marrow Cells Derived From Patients with Acute Myeloid Leukemia.

The Polyamide-Chlorambucil Conjugate 1R-Chl Effectively Inhibits Proliferation and Induces Apoptosis in CML Progenitor Cells

Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.

Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment.

MAPK-Activation in CD34+ CML Stem Cells Induced by Selective Abl-Inhibitors Is Not Observed Using the Combined Src/Abl-Inhibitor Dasatinib.

The Dual Src/Abl Kinase Inhibitor SKI-606 Effectively Inhibits Bcr-Abl Kinase Activity and Reduces Proliferation of CML Primitive Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only